NCT06987773View on ClinicalTrials.gov

Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

August 30, 2025

Study Completion Date

September 30, 2025

Conditions
Bioequivalence
Interventions
DRUG

RLF-OD032 100 mg/mL oral suspension

Sapropterin dihydrochloride

DRUG

Kuvan 100 MG Powder for Oral Solution

Sapropterin dihydrochloride

Sponsors
All Listed Sponsors
lead

APR Applied Pharma Research s.a.

OTHER